Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls

References

• Yang L, Chai P, Yu J, Fan X. Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants. Cancer Biol Med. 2021;18(1):1–12. doi:10.20892/j.issn.2095-3941.2020.0559.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu C-Y, Desai A, de Lima Lopes G, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907–1918. doi:10.1016/S0140-6736(20)31187-9.
   PubMed Web of Science ®Google Scholar
• Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–337. doi:10.1016/S1470-2045(20)30096-6.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Safety and efficacy of the ChAdox1 nCov-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. doi:10.1016/S0140-6736(20)32661-1.
   PubMed Web of Science ®Google Scholar
• El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. 2021;385(19):1774–1785. doi:10.1056/NEJMoa2113017.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Van Dromme I, Spiessens B, et al. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S. N Engl J Med. 2022;386(9):847–860. doi:10.1056/NEJMoa2117608.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, Neuzil KM, Hahn W, Hunt J, Mulligan MJ, et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdox1 nCov-19) Covid-19 Vaccine. N Engl J Med. 2021;385(25):2348–2360. doi:10.1056/NEJMoa2105290.
   PubMed Web of Science ®Google Scholar
• Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, Hussein K, Fahoum L, Baruch M, Peer A, et al. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. JAMA Oncol. 2021;7(10):1507–1513. doi:10.1001/jamaoncol.2021.2675.
   PubMed Web of Science ®Google Scholar
• Oosting SF, van der Veldt AAM, GeurtsvanKessel CH, Fehrmann RSN, van Binnendijk RS, Dingemans AC, Smit EF, Hiltermann TJN, den Hartog G, Jalving M, et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncol. 2021;22(12):1681–1691. doi:10.1016/S1470-2045(21)00574-X.
   PubMed Web of Science ®Google Scholar
• Bettini E, Locci M. SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. Vaccines (Basel). 2021;9(2). doi:10.3390/vaccines9020147.
   PubMed Web of Science ®Google Scholar
• Dong Y, Dai T, Wei Y, Zhang L, Zheng M, Zhou F. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5(1):237. doi:10.1038/s41392-020-00352-y.
   PubMed Web of Science ®Google Scholar
• Tadele Admasu F. Knowledge and Proportion of COVID-19 Vaccination and Associated Factors Among Cancer Patients Attending Public Hospitals of Addis Ababa, Ethiopia, 2021: a Multicenter Study. Infect Drug Resist. 2021;14:4865–4876. doi:10.2147/IDR.S340324.
   PubMed Web of Science ®Google Scholar
• Peng X, Gao P, Wang Q, Wu H-G, Yan Y-L, Xia Y, Wang J-Y, Lu F, Pan H, Yang Y, et al. Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy Among Breast Cancer Survivors: a Multicenter Cross-Sectional Study in China. Front Med. 2021;8. doi:10.3389/fmed.2021.741204
   Web of Science ®Google Scholar
• Cherif I, Khiari H, M’-Ghirbi F, Mallekh R, Mezlini A, and Hsairi M. COVID-19 vaccine hesitancy among Tunisian cancer patients in the Salah Azaeiz Institute of Cancer. Eur J Public Health. 2021;31(Supplement_3):iii359. doi:10.1093/eurpub/ckab165.056.
   Google Scholar
• Di Noia V, Renna D, Barberi V, Di Civita M, Riva F, Costantini G, Aquila ED, Russillo M, Bracco D, La Malfa AM, et al. The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey. Eur J Cancer. 2021;153:260–264. doi:10.1016/j.ejca.2021.05.006.
   PubMed Web of Science ®Google Scholar
• Mejri N, Berrazega Y, Ouertani E, Rachdi H, Bohli M, Kochbati L, Boussen H. Understanding COVID-19 vaccine hesitancy and resistance: another challenge in cancer patients. Support Care Cancer. 2022;30(1):289–293. doi:10.1007/s00520-021-06419-y.
   PubMed Web of Science ®Google Scholar
• Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, Pletcher MJ, Marcus GM. Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination. JAMA Netw Open. 2021;4(12):e2140364. doi:10.1001/jamanetworkopen.2021.40364.
   PubMed Web of Science ®Google Scholar
• Nachtigall I, Bonsignore M, Hohenstein S, Bollmann A, Günther R, Kodde C, et al. Effect of gender, age and vaccine on reactogenicity and incapacity to work after COVID-19 vaccination: a survey among health care workers. BMC Infect Dis. 2022;22(1):291. doi:10.1186/s12879-022-07284-8.
   PubMed Web of Science ®Google Scholar
• Rolfes L, Härmark L, Kant A, van Balveren L, Hilgersom W, van Hunsel F. COVID-19 vaccine reactogenicity - a cohort event monitoring study in the Netherlands using patient reported outcomes. Vaccine. 2022;40(7):970–976. doi:10.1016/j.vaccine.2022.01.013.
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–656. doi:10.1097/00000421-198212000-00014.
   PubMed Web of Science ®Google Scholar
• FDA US. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials, Guidance for Industry September 2007. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical.
   Google Scholar
• Teeyapun N, Wanchaijiraboon PP, Pakvisal N, Sainamthip P, Phaibulvatanapong E, Wanlapakorn N, Poovorawan Y, Luangdilok S. HSR22-172-HSR22-172: Immunogenicity of ChAdOx1-nCoV-19 Vaccination for Solid Cancer Patients, Prospective Observational Multicenter Study - Preliminary Report. J Nat Compr Cancer Netw. 2022;20(3.5):HSR22–172. doi:10.6004/jnccn.2021.7215.
   Google Scholar
• Wanlapakorn N, Suntronwong N, Phowatthanasathian H, Yorsaeng R, Vichaiwattana P, Thongmee T, Auphimai C, Srimuan D, Thatsanatorn T, Assawakosri S, et al. Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study. Hum Vaccin Immunother. 2022;18(1):2029111. doi:10.1080/21645515.2022.2029111.
   PubMed Web of Science ®Google Scholar
• Parida SP, Sahu DP, Singh AK, Alekhya G, Subba SH, Mishra A, Padhy BM, Patro BK. Adverse events following immunization of COVID-19 (Covaxin) vaccine at a tertiary care center of India. J Med Virol. 2022;94(6):2453–2459. doi:10.1002/jmv.27655.
   PubMed Web of Science ®Google Scholar
• Jeon M, Kim J, Oh CE, and Lee JY. Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdox1 nCov-19 Vaccine among Healthcare Workers in Korea. Vaccines (Basel). 2021;9(10):3–5. doi:10.3390/vaccines9101096.
   Web of Science ®Google Scholar
• Frater J, Ewer KJ, Ogbe A, Pace M, Adele S, Adland E, Alagaratnam J, Aley PK, Ali M, Ansari MA, et al. Safety and immunogenicity of the ChAdox1 nCov-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV. 2021;8(8):e474–e85. doi:10.1016/S2352-3018(21)00103-X.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Koen AL, Izu A, Fairlie L, Cutland CL, Baillie V, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, et al. Safety and immunogenicity of the ChAdox1 nCov-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021;8(9):e568–e80. doi:10.1016/S2352-3018(21)00157-0.
   PubMed Web of Science ®Google Scholar
• Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol. 2021;21(8):475–484. doi:10.1038/s41577-021-00578-z.
   PubMed Web of Science ®Google Scholar
• Schmidt T, Klemis V, Schub D, Schneitler S, Reichert MC, Wilkens H, Sester U, Sester M, Mihm J. Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients. Am J Transplant. 2021;21(12):3990–4002. doi:10.1111/ajt.16818.
   PubMed Web of Science ®Google Scholar
• Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, et al. Safety and immunogenicity of ChAdox1 nCov-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396(10267):1979–1993. doi:10.1016/S0140-6736(20)32466-1.
   PubMed Web of Science ®Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, et al. Safety and immunogenicity of the ChAdox1 nCov-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–478. doi:10.1016/S0140-6736(20)31604-4.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. N Engl J Med. 2020;383(20):1920–1931. doi:10.1056/NEJMoa2022483.
   PubMed Web of Science ®Google Scholar
• Naranbhai V, Pernat CA, Gavralidis A, Denis KJS, Lam EC, Spring LM, Isakoff SJ, Farmer JR, Zubiri L, Hobbs GS, et al. Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients with Cancer: the CANVAX Cohort Study. J Clin Oncol. 2022;40(1):12–23. doi:10.1200/JCO.21.01891.
   PubMed Web of Science ®Google Scholar
• Yang J, Ko J-H, Baek JY, Hong J, Ha S, Lee B, Huh K, Cho SY, Kang C-I, and Chung DR, et al. Effects of Short-Term Corticosteroid Use on Reactogenicity and Immunogenicity of the First Dose of ChAdox1 nCov-19 Vaccine. Front Immunol. 2021;12:3–5. doi:10.3389/fimmu.2021.744206.
   Web of Science ®Google Scholar